ArgenX is a startup based in the Netherlands, most recent round Series-c-plus, 3 tracked investors.
Based in the Netherlands, ArgenX is a startup. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
ArgenX is a global immunology company focused on developing antibody therapies for severe autoimmune diseases, with a primary product, VYVGART, approved for treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.